Biosimilar Index: Tracking the Global Biosimilar Pipeline
- There are 15 biosimilar and non-comparable biologic (NCB) versions of bevacizumab (Avastin; Roche) in clinical development; with the Biosimilar Index you can know who is developing them, in which indications and what stage they’re at
- Biosimilars and NCBs are being developed across 13 discreet therapy areas; investigate what are they and which areas dominate
- There are 40 biosimilar and NCB programmes in Phase III trials; benefit from knowing who is developing them and what reference products are being targeted
- There are 115 monoclonal antibodies out of a current total of 385 products in Biosimilar Index; make sure you know what classes of drug the other 270 are being developed for
- Rituximab (Rituxan/MabThera; Roche) is top of the biosimilar and NCB development league, with over 30 individual programmes around the globe
The prospect of a biosimilars market has been long in development and is now on the cusp of delivering real value as high-value brands lose patent protection.
Biosimilar R&D activity is at an all-time high and, at this critical stage in the market’s evolution, it is vital to fully understand the biosimilar and non-comparable biologic (NCB) pipeline and be able to draw reliable conclusions about what is, and is not, significant. That is where the Biosimilar Index comes in.
A new force in biosimilar and NCB drug and market tracking
FirstView’s Biosimilar Index is a new, comprehensive drug intelligence service which provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.
Two class beating services in one subscription!
- Biosimilar Index: Pipeline Database Updated as new market information becomes available, this Database provides up-to-date insight of over 380 (and growing) biosimilar and NCB drugs in development from over 130 companies worldwide. The Database can be downloaded (as often as you need) in MS Excel format.
- Biosimilar Index: Landscape Review Published quarterly and delivered by email in MS PowerPoint, the Landscape Review is packed with slides of tables and charts on key reference medicinal product data, current and future market milestones, extensive product-by product reviews and relevant clinical trial activity. The Landscape Review is based on the updated research in the Biosimilar Index: Pipeline Database and enhanced by critical insights from in house and external biosimilar experts.
Whether you work in big pharma, a biosimilars development company, a clinical service organisation, a regulatory body or in commercial investment and finance, the Biosimilar Index provides a clear window on the world of biosimilar drugs and their developers.
Key benefits at a glance
- Access a comprehensive dynamically updated database in downloadable format
- Receive a quarterly Review which analyses development and puts them in clinical and commercial context
- Save time from a service harnessing a wide-range of quality information sources
- Benefit from the knowledge and experience of our expert researchers and analysts
Legally, only the US has a formal definition for a biosimilar. Under the Affordable Care Act of 2010, a biological product may be demonstrated to be biosimilar if “…data show that, among other things, the product is ‘highly similar’ to an already-approved biological product.”
For the purposes of The Biosimilar Index, a product will be deemed to be a biosimilar if it is being, or has been, developed via a rigorous comparability exercise versus an approved reference medicinal product (RMP) that has been laid down as part of national biosimilar guidelines (e.g. EMA, FDA, etc.).
Within the database, we specify which products are deemed to be biosimilars based on local guidelines vs. those products deemed to be non-comparable biologics (i.e. have not been studied comparatively, and are likely only be launched locally). Due to FirstView’s area of expertise, we are unable to provide guidance to clients on regulatory issues.
